Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 May 26;210(9):1419–1430. doi: 10.1093/infdis/jiu284

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.

PMC Copyright notice

Figure 5. — Incidence of solicited symptoms after the administration of trivalent seasonal influenza vaccine (TIV) or placebo and after each of the 2 doses of A(H1N1)pdm09 vaccine. Mean percentage of participants with 95% confidence interval (CI) experiencing solicited local (A) and general (B) adverse events (AEs) reported within 7 days postvaccination are shown for all participants for whom at least 1 administration of vaccine or placebo was documented (the total vaccinated cohort). Group A received TIV at day 0 and A(H1N1)pdm09 (3.75 µg)/AS03 at day 122 and day 143. Group B received TIV at day 0 and A(H1N1)pdm09 (15 µg) at day 122 and day 143. Group C received saline at day 0 and A(H1N1)pdm09 (3.75 µg)/AS03 at day 122 and day 143. Group D received saline at day 0 and A(H1N1)pdm09 (15 µg) at day 122 and day 143.